Skip to content
GLP1-US
Prices checked Wegovy pill $149 Wegovy pen $349 Zepbound $299–449 Foundayo from $149 Ozempic $349 Medicare Bridge $50 Compounded sema $175 All prices →

FDA label and CMS Medicare guidance checked Oct 2026

Wegovy for Heart Risk: What the SELECT Approval Covers

Since Mar 8, 2024, Wegovy is FDA-approved to lower the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight. In the SELECT trial it cut those events by 20%.

  • FDA-approved for this use
  • No diabetes required
  • Medicare Part D can cover it
  • Not a heart failure treatment

We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure

By GLP1-US Editorial TeamUpdated
★ Editor's Choice
Chia Health logo

Chia Health

Our #1 pick for GLP-1 weight loss online

  • One monthly price: clinician, medication and free shipping included
  • Semaglutide or tirzepatide, as a weekly injection or a daily tablet
  • No insurance needed; HSA/FSA and Klarna accepted

Compounded medications, not FDA-approved. Prices checked Nov 17, 2026. Advertiser Disclosure

$212.89 first month, then $349/mo

6-month plan: $249/mo, paid upfront ($1,396.89 for the first 6 months). Microdose: $109.19 first month, then $179/mo.

Get Started Read our Chia Health review

01 The approval

What the FDA Approved for Wegovy and the Heart

On March 8, 2024, the FDA approved Wegovy (semaglutide) injection "to reduce the risk of major adverse cardiovascular events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight." The FDA called it the first treatment approved to reduce the risk of serious heart problems specifically in adults with obesity or overweight. The Wegovy pill gained the same indication with its own approval on December 22, 2025.

Approved
Mar 8, 2024

pen; pill Dec 22, 2025

Who
Adults with heart disease

plus obesity or overweight

Pen dose
2.4 mg/week

1.7 mg if 2.4 mg is not tolerated

Not included
Wegovy HD

7.2 mg is weight-only

"Established CV disease" in the trial meant a prior heart attack, a prior stroke or peripheral artery disease. Obesity means a BMI of 30 or more, overweight 27 to 29.9; check yours with our BMI calculator. The dose climbs over 16 weeks from 0.25 mg, the same schedule as for weight loss; see Wegovy dosage.

02 Trial results

SELECT Trial Results, Event by Event

SELECT randomized 17,604 adults aged 45 or older to Wegovy 2.4 mg or placebo on top of standard heart care: 90% took a cholesterol drug and 86% an antiplatelet drug. Median follow-up was 41.8 months. Only the first row was the primary endpoint; the others are context, and the label is careful about which ones were proven.

EventPlaceboWegovy
Heart attack, stroke or CV death (primary)
HR 0.80 (0.72 to 0.90) · Significant
8.0% 6.5%
Heart attack, fatal or not
HR 0.72 (0.61 to 0.85) · Not in testing hierarchy
3.8% 2.8%
Stroke, fatal or not
HR 0.89 (0.72 to 1.11) · Not in testing hierarchy
2.0% 1.8%
Cardiovascular death
HR 0.85 (0.71 to 1.01) · Superiority not confirmed
3.0% 2.5%
Death from any cause
HR 0.81 (0.71 to 0.93) · Not significant in hierarchy
5.2% 4.3%
Heart failure hospitalization or urgent visit
HR 0.79 (0.60 to 1.03) · Effect not established
1.4% 1.1%

Share of patients with at least one event. Source: Wegovy prescribing information, section 14.1, Table 6, revised 06/2026.

At week 104, weight was down 9.4% on Wegovy versus 0.9% on placebo, and systolic blood pressure fell 3.8 versus 0.5 mmHg (label Table 7). The label adds that the benefit held regardless of age, sex, race, starting BMI or kidney function. Heart rate rose by about 3 beats a minute versus placebo.

03 Eligibility

Who Qualifies for Wegovy to Lower Heart Risk

  • 1

    Adult with established cardiovascular disease. In SELECT: a prior heart attack (76% of patients), prior stroke (23%) or peripheral artery disease (9%).

  • 2

    BMI of 27 or higher. The trial's average BMI was 33.

  • 3

    Usually no type 2 diabetes. SELECT excluded diabetes. If you have it, Ozempic already carries a heart-risk approval for type 2 diabetes with heart disease, and your prescriber weighs both.

  • 4

    Staying on your heart medicines. Wegovy is added to statins, blood thinners and blood pressure drugs, not swapped for them. Some insurers require that you take them.

  • 5

    No medullary thyroid cancer or MEN 2 in you or your family; these are label contraindications.

04 Insurance

Wegovy Heart Risk Insurance: Separate Criteria From Weight Loss

Many commercial plans that exclude weight-loss drugs review Wegovy for heart risk under a separate policy. Ask the plan for "Wegovy for cardiovascular risk reduction" by name.

UnitedHealthcare

Covered with prior authorization even on plans that exclude weight loss: age 45+, BMI 27+, prior heart attack, stroke or symptomatic PAD, and on standard heart medicines (policy P 1445-4, May 1, 2026). Details.

CVS Caremark / Aetna

Heart-risk requests have their own criteria in the 5098-C policy; Wegovy HD is not included. Details.

Blue Cross plans

Blue Cross VT still covers Wegovy for heart disease with obesity despite a weight-loss exclusion; BCBS of South Carolina may cover it for heart risk with PA from Aug 1, 2026. Details.

If approved on a commercial plan, the Wegovy savings card can bring a fill to as little as $25 (maximum savings $100 a month). If denied: appeal, or self-pay at $349/mo for the pen. More in Wegovy insurance and Wegovy cost.

05 Medicare

Medicare for Wegovy Heart Risk: Part D, Not the Bridge

Heart risk is the use that first opened Medicare to Wegovy: in March 2024 CMS confirmed that an obesity drug approved for another medically accepted use can be a Part D drug for that use. CMS now says a prescription written "in order to" reduce heart attack and stroke risk goes to your Part D plan. Having heart disease does not bar you from the Bridge if the drug is prescribed for weight management.

TopicPart D plan (heart risk)GLP-1 Bridge (weight)
Prescribed toLower heart attack, stroke and CV death riskManage weight
WhoEstablished heart disease plus BMI 27+BMI 35 or higher; or BMI 30 or higher with heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension or chronic kidney disease stage 3a or higher; or BMI 27 or higher with prediabetes, a prior heart attack, a prior stroke or symptomatic peripheral artery disease
You payYour plan's copay or coinsurance$50/mo
DatesOngoingJul 1, 2026 to Dec 31, 2027
Savings cardNot allowedNot allowed

Sources: CMS Bridge information for Part D plans; KFF, March 2024. Full rules: Medicare GLP-1 Bridge and Medicare coverage.

On Medicare and want a clinician to sort out which route fits you? Telehealth primary care can write the prescription and paperwork.

See a clinician through Amazon One Medical

06 Cost

Wegovy Price for Heart Risk Without Insurance

Pen, NovoCare
$349/mo

$199 for the first 2 fills

Pill, NovoCare
$149–$299/mo

by dose

List price
$1,349.02

per 4-pen box

$199/mo for the first 2 fills at 0.25 and 0.5 mg (new NovoCare patients, through Dec 31, 2026), then $349/mo for 0.25–2.4 mg. Wegovy HD 7.2 mg $399/mo. Source: NovoCare, Oct 2026. Compare pen and pill: Wegovy pill vs injection.

07 FAQ

Wegovy Heart Risk FAQ

Is Wegovy approved for heart disease?
Yes, for risk reduction. Since March 8, 2024, Wegovy is FDA-approved to lower the risk of cardiovascular death, heart attack and stroke in adults with established heart disease and either obesity or overweight, with diet and exercise. It does not treat heart failure; the label says that effect has not been established.
How much does Wegovy lower heart attack and stroke risk?
In the SELECT trial of 17,604 adults followed for a median 41.8 months, 6.5% on Wegovy had a heart attack, stroke or cardiovascular death versus 8.0% on placebo. That is a 20% lower relative risk (hazard ratio 0.80), or about 1.5 fewer events per 100 people.
Do I need diabetes to get Wegovy for heart risk?
No. SELECT excluded people with diabetes, so this approval is aimed at people without it. People with type 2 diabetes and heart disease already have GLP-1 options approved for heart risk, such as Ozempic, so their prescriber usually starts there.
Does Medicare cover Wegovy for heart disease?
Yes, through your Part D plan, when Wegovy is prescribed to reduce heart attack and stroke risk in established heart disease. CMS routes those prescriptions to the Part D plan, so your plan copay applies, not the $50 Bridge. If it is prescribed for weight management instead, the Bridge can apply.
Is the Wegovy pill approved for heart risk too?
Yes. The Wegovy tablet label carries the same heart-risk indication for adults with established heart disease and obesity or overweight. Wegovy HD 7.2 mg does not; it is a weight-management dose only.
How much is Wegovy for heart risk without insurance?
The price does not change with the reason. As of October 2026 NovoCare charges $349 a month for the pen at any dose up to 2.4 mg, with the first two fills at $199 for new patients through December 31, 2026. The pill costs $149 to $299 a month by dose.

Other approved uses: what GLP-1 is used for · Wegovy for MASH · Ozempic for kidney disease.

Medical Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or qualified health provider with any questions about a medical condition or medication. Never disregard professional medical advice or delay seeking it because of something you have read on this website.

Checked against primary sources such as FDA labels, CMS and provider pages
Updated
How we check facts →